hypertonic dextrose water
PreclinicalSmall molecule
hypertonic dextrose water is one of 11 small molecule programs targeting Bursitis. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
11 competitors in Bursitis
#DrugCompanyPhaseTrials
1Medrol
PfizerApproved
Aleve
Jazz PharmaceuticalsApproved
Kenalog
BBausch Health Americas, Inc.
Approved
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Rayos
RRoxane Laboratories
Approved
Oruvail
WWyeth-Lederle Vaccines
Approved
Kenalog
BBassett Healthcare
Preclinical
Arcalyst
KKiniksa Pharmaceuticals (UK), Ltd.
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Naproxen Sodium
BayerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for hypertonic dextrose water. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details